Senti Bio Board Member Shows Long-term Commitment with New Stock Option Grant

Rhea-AI Filing Summary

Form 4 filing reveals that Donald F. Tang, Director at Senti Biosciences (SNTI), received a stock option grant on June 25, 2025. The derivative securities transaction details include:

• Granted 21,950 stock options to purchase common stock
• Exercise price set at $2.05 per share
• Options expire on June 24, 2035
• Vesting schedule: 100% vests at earlier of: - First anniversary of grant date - Date of 2026 Annual Meeting

Vesting is contingent on Tang's continued service through the applicable vesting date. The transaction was reported through an attorney-in-fact, Robert Cutler, on June 27, 2025. This equity compensation aligns with standard director compensation practices and aims to align the director's interests with shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tang Donald F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	21,950	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 21,950 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tang Donald F

(Last) (First) (Middle)

C/O SENTI BIOSCIENCES, INC.

2 CORPORATE DRIVE FIRST FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.05	06/25/2025		A		21,950		(1)	06/24/2035	Common Stock	21,950	$0	21,950	D

Explanation of Responses:

1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Robert Cutler, attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did SNTI director Donald Tang receive on June 25, 2025?

Donald Tang received 21,950 stock options (right to buy) of SNTI common stock with an exercise price of $2.05 per share.

What are the vesting terms for SNTI director Donald Tang's stock options granted in June 2025?

The stock options vest 100% upon the earlier of (i) the first anniversary of the grant date (June 25, 2026) or (ii) the date of the 2026 Annual Meeting, subject to Tang's continued service through the applicable vesting date.

When do Donald Tang's SNTI stock options expire?

The stock options granted to Donald Tang expire on June 24, 2035, ten years from the grant date.

What is the exercise price of SNTI stock options granted to director Donald Tang in June 2025?

The exercise price of the stock options granted to Donald Tang is $2.05 per share.

What position does Donald Tang hold at SNTI according to the Form 4 filing?

According to the Form 4 filing, Donald Tang serves as a Director of Senti Biosciences, Inc. (SNTI).